Oral Allergen-Specific Immunotherapy (OIT) has been shown to improve the response threshold to the culprit food allergen in children with chronic IgE-mediated Food Allergy (FA) to cow's milk, hen's egg, and peanuts. In the event that the culprit meal is accidentally consumed during therapy, OIT may prevent patients from severe responses. Despite this, several questions remain unanswered, including safety concerns, the development of predictive biomarkers, and the efficacy of post-desensitization treatment. In this regard, the use of omalizumab (Anti-IgE monoclonal antibody) as an adjuvant therapy to OIT has been recommended in order to lower the risk of OIT-related allergic responses.
